The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology.
Ulcerative colitis (uc) is a chronic condition and for the vast majority of patients, life-long treatment is required. low adherence to therapy is an emerging issue. since low adherence is associated with poor clinical outcomes and increased costs, it is becoming crucial to identify strategies in order to improve it. Areas covered: We performed literature searches in PubMed using the terms 'adherence', 'mesalamine', 'budesonide MMX', 'MMX technology' in combination with 'ulcerative colitis'. Firstly, we present the key-concepts of therapy for UC and discuss the problem of the adherence and how to measure it. Then, we provide data on the extent of the problem and the causes and consequences from clinical and economic point of views. Finally, we focus on treatment-related variables associated with non-adherence and treatment-related strategies to improve adherence, paying particular attention to Multi Matrix system (MMX) technology applied to mesalazine and budesonide. Expert commentary: The pharmaceutical industry and scientific community are making efforts to simplify treatments for UC. MMX technology, which allows a reduction in the number of pills to be taken and daily administrations, may facilitate adherence to treatment and carry further clinical benefits.
a Gastroenterology Unit , Rho Hospital, ASST Rhodense , Garbagnate Milanese , Italy.
Cristina
C
Bezzio
b Internal Medicine Unit , dell'Angelo Hospital , Mestre , Italy.
Federica
F
Fascì-Spurio
c Gastroenterology Unit , San Gerardo Hospital , Monza , Italy.
Chiara
C
Viganò
d Gastroenterology Unit , San Giuseppe Hospital , Milano , Italy.
Gianmichele
G
Meucci
e Gastroenterology Unit , San Filippo Neri Hospital , Rome , Italy.
Claudio
C
Papi
a Gastroenterology Unit , Rho Hospital, ASST Rhodense , Garbagnate Milanese , Italy.
Simone
S
Saibeni
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D019819:Budesonide / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004339:Drug Compounding; D004359:Drug Therapy, Combination; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D006801:Humans; D055118:Medication Adherence; D019804:Mesalamine / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D011108:Polymers / Q000737:chemistry*; D012074:Remission Induction; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D005765:Gastrointestinal Agents; D011108:Polymers; D019804:Mesalamine; D019819:Budesonide
MMX; Ulcerative colitis; adherence; budesonide; mesalazine; multi-matrix system technology; therapy